Park Square has placed Nelson Azoulay as Senior Vice President of Strategy and Business Development at Flagship Pioneering. In this role, he leverages his expertise in corporate strategy, cross-functional leadership, and deal-making to spearhead business development initiatives that fuel growth and innovation across Flagship companies.

Previously, Nelson served as Vice President of Corporate Development at ImmunoGen, where he designed and implemented the company’s mid- to long-term strategy, led search and evaluation efforts, and secured key transactions, including early-research collaborations and platform-validating partnerships with Eli Lilly and Vertex. He also played a pivotal role in fundraising activities, the company acquisition by AbbVie in 2024, and subsequent integration.

 Before his tenure at ImmunoGen, Nelson was Senior Director at PDL BioPharma, where he oversaw corporate restructuring efforts and managed strategic divestitures involving a pharma company, royalties, and investments. Earlier in his career, at Syneos Health Consulting, he led over 50 engagements with global pharmaceutical and biotechnology companies, providing strategic guidance on portfolio strategy, sell- and buy-side transactions, and commercial planning.

 Nelson earned his MBA from Columbia Business School with a focus on finance and entrepreneurship, an MS in Neuroscience from McGill University, where his research centered on epigenetics, and a BA from Wesleyan University.